Targeting The Myeloid Checkpoint Receptor Sirp Alpha Potentiates Innate And Adaptive Immune Responses To Promote Anti-Tumor Activity

Tracy C Kuo,Amy Chen,Ons Harrabi,Jonathan T Sockolosky,Anli Zhang,Emma Sangalang,Laura V Doyle,Steven E Kauder,Danielle Fontaine,Sangeetha Bollini,Bora Han,Yang-Xin Fu,Janet Sim,Jaume Pons,Hong I Wan
DOI: https://doi.org/10.1186/s13045-020-00989-w
IF: 28.5
2020-01-01
Journal of Hematology & Oncology
Abstract:Background Signal regulatory protein alpha (SIRP alpha) is a myeloid-lineage inhibitory receptor that restricts innate immunity through engagement of its cell surface ligand CD47. Blockade of the CD47-SIRP alpha interaction synergizes with tumor-specific antibodies and T-cell checkpoint inhibitors by promoting myeloid-mediated antitumor functions leading to the induction of adaptive immunity. Inhibition of the CD47-SIRP alpha interaction has focused predominantly on targeting CD47, which is expressed ubiquitously and contributes to the accelerated blood clearance of anti-CD47 therapeutics. Targeting SIRP alpha, which is myeloid-restricted, may provide a differential pharmacokinetic, safety, and efficacy profile; however, SIRP alpha polymorphisms and lack of pan-allelic and species cross-reactive agents have limited the clinical translation of antibodies against SIRP alpha. Here, we report the development of humanized AB21 (hAB21), a pan-allelic anti-SIRP alpha antibody that binds human, cynomolgus monkey, and mouse SIRP alpha alleles with high affinity and blocks the interaction with CD47. Methods Human macrophages derived from donors with various SIRP alpha v1 and v2 allelic status were used to assess the ability of hAB21 to enhance phagocytosis. HAB21_IgG subclasses were evaluated for targeted depletion of peripheral blood mononuclear cells, phagocytosis and in vivo efficacy in xenograft models. Combination therapy with anti-PD1/anti-PD-L1 in several syngeneic models was performed. Immunophenotyping of tissues from MC38 tumor-bearing mice treated with AB21 and anti-PD-1 was evaluated. PK, PD and tolerability of hAB21 were evaluated in cynomolgus monkeys. Results SIRP alpha blockade with hAB21 promoted macrophage-mediated antibody-dependent phagocytosis of tumor cells in vitro and improved responses to rituximab in the Raji human tumor xenograft mouse model. Combined with PD-1/PD-L1 blockade, AB21 improved response rates by facilitating monocyte activation, dendritic cell activation, and T cell effector functions resulting in long term, durable antitumor immunity. In cynomolgus monkeys, hAB21 has a half-life of 5.3 days at 10 mg/kg and complete target occupancy with no hematological toxicity or adverse findings at doses up to 30 mg/kg. Conclusions The in vitro and in vivo antitumor activity of hAB21 broadly recapitulates that of CD47 targeted therapies despite differences in ligand expression, binding partners, and function, validating the CD47-SIRP alpha axis as a fundamental myeloid checkpoint pathway and its blockade as promising therapeutic intervention for treatment of human malignancies.
What problem does this paper attempt to address?